CTLA4 and head and neck squamous cell carcinoma: Among the ICIs currently used in HNSCC, ipilimumab against CTLA-4 and atezolizumab and durvalumab against PD-L1 are IgG1, while nivolumab and pembrolizumab against PD-1 are IgG4.